Numais Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Numais General Information
Description
Developer of a diagnostic treatment intended for vascular stenosis and atherosclerosis. The company uses state-of-the-art synthesis methodologies on the stem-cell-derived nanovesicle theranostics and the thermo-sensitive biodegradable hydrogel delivery systems to maximize the efficacy of the stem-cell therapeutics and the predictability of drug delivery systems, enabling patients to improve the grade of life for those suffering from various types of inflammatory diseases.
Contact Information
Website
www.numais.comCorporate Office
- 2nd Floor, Room Numbers 201, 202, 203, SKV E1 Center 2
- 31 Gwangnaru-ro 8-gil, Seongdong-gu
- Seoul
- South Korea
Corporate Office
- 2nd Floor, Room Numbers 201, 202, 203, SKV E1 Center 2
- 31 Gwangnaru-ro 8-gil, Seongdong-gu
- Seoul
- South Korea
Numais Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 23-Jan-2024 | Completed | Out of Business | |||
| 2. Early Stage VC | 07-May-2021 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 07-Jun-2020 | $3.17M | $3.17M | Completed | Startup |
Numais Patents
Numais Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022245144-A1 | Method for production of cell-derived nanovesicles by using high-pressure fluid dispersion | Inactive | 20-May-2021 | ||
| WO-2022240243-A1 | Skin-whitening composition containing nanovesicles | Inactive | 14-May-2021 | ||
| JP-2022546423-A | Diagnosis and treatment of arteriosclerosis using blood flow alteration site-targeting nanovesicles | Pending | 30-Aug-2019 | ||
| EP-4024048-A1 | Method for diagnosing and treating atherosclerosis by using nanovesicle targeting site of change in blood flow | Inactive | 30-Aug-2019 | ||
| EP-4024048-A4 | Method for diagnosing and treating atherosclerosis by using nanovesicle targeting site of change in blood flow | Inactive | 30-Aug-2019 | G01N33/6893 |
Numais Signals
Numais FAQs
-
When was Numais founded?
Numais was founded in 2019.
-
Where is Numais headquartered?
Numais is headquartered in Seoul, South Korea.
-
What is the size of Numais?
Numais has 3 total employees.
-
What industry is Numais in?
Numais’s primary industry is Drug Delivery.
-
Is Numais a private or public company?
Numais is a Private company.
-
What is Numais’s current revenue?
The current revenue for Numais is .
-
How much funding has Numais raised over time?
Numais has raised $6.03M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process